Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Beginning Cash Balance Beginning Cash Balance Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Preferred Shares Repurchased Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

PharmaCyte Biotech (PMCB) Cash from Investing Activities (2024 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Cash from Investing Activities for 7 consecutive years, with $5.0 million as the latest value for Q1 2026.

Quarterly Cash from Investing Activities changed N/A to $5.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Jan 2026, up 128.57% year-over-year, with the annual reading at -$7.0 million for FY2025, 40.0% down from the prior year.
Cash from Investing Activities for Q1 2026 was $5.0 million at PharmaCyte Biotech, up from -$3.0 million in the prior quarter.
The five-year high for Cash from Investing Activities was $5.0 million in Q1 2026, with the low at -$7.0 million in Q3 2024.
Average Cash from Investing Activities over 3 years is -$2.5 million, with a median of -$4.0 million recorded in 2024.